DSDaouda Sanogo

Daouda Sanogo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daouda Sanogo has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Relationship between Nutritional Status and Malaria Risk among Children Receiving Routine Seasonal Malaria Chemoprevention: Evidence from a Prospective Cohort Study in Mali

    by Soumba Keita, Mahamoudou Toure, Fousseyni Kane, Hamady Coulibaly, Daouda Sanogo, Ibrahim Sanogo, Drissa Konate, Idiatou Diallo, Moussa Keita, Sory Ibrahim Diawara, et al.

    Background: While Seasonal Malaria Chemoprevention (SMC) has substantially reduced malaria burden among children, malaria remains common in areas with high prevalence of malnutrition. This study assessed the relationship between nutritional status and malaria risk in children in a context of routine SMC campaign.Methods: A prospective cohort study of 425 children aged 3-59 months enrolled prior to the first SMC round in Sirakorola, Mali. Based on WHO 2006 growth standards, 181 children were classified as malnourished and 244 as having normal nutritional status; severe acute malnutrition cases were excluded. Monthly anthropometric measures, SMC coverage, and malaria infection data were collected from July to October. Malaria episodes were monitored through passive case detection between SMC cycles. Mixed-effects Poisson regression models estimated associations with malaria incidence and assessed changes in nutritional status and adherence to SMC campaign.Results: SMC coverage was high, with over 80% of children completing at least three rounds in both groups. Despite similar coverage, malnourished children had higher prevalence of Plasmodium falciparum infection (6.5% vs 2.6%; OR = 2.1, 95% CI 1.3-3.7) and higher clinical malaria incidence (9.1 vs 6.0 per 100 person-months; IRR = 1.4, 95% CI 1.0-2.0). Increased malaria risk was associated with baseline malnutrition (IRR = 1.6, 95% CI: 1.0-2.5) and receiving < 3 rounds (IRR = 3.0, 95% CI: 1.4-6.5). The interaction between nutritional status and SMC exposure was not significant (IRR = 0.8, 95% CI 0.2-3.6, p = 0.746). Improvements in nutritional indicators were observed among children completing 3-4 rounds in both groups. Conclusion: Malnutrition was independently associated with increased malaria risk, however adherence to routine SMC campaigns reduces the risk of malaria and improves nutritional status. Thus, integrating nutritional intervention with SMC is needed to enhance Child health in high-burden settings.

  • Open Access

    Relationship between Nutritional Status and Malaria Risk among Children Receiving Routine Seasonal Malaria Chemoprevention: Evidence from a Prospective Cohort Study in Mali

    by Soumba Keita, Mahamoudou Toure, Fousseyni Kane, Hamady Coulibaly, Daouda Sanogo, Ibrahim Sanogo, Drissa Konate, Idiatou Diallo, Moussa Keita, Sory Ibrahim Diawara, et al.

    Background: While Seasonal Malaria Chemoprevention (SMC) has substantially reduced malaria burden among children, malaria remains common in areas with high prevalence of malnutrition. This study assessed the relationship between nutritional status and malaria risk in children in a context of routine SMC campaign.Methods: A prospective cohort study of 425 children aged 3-59 months enrolled prior to the first SMC round in Sirakorola, Mali. Based on WHO 2006 growth standards, 181 children were classified as malnourished and 244 as having normal nutritional status; severe acute malnutrition cases were excluded. Monthly anthropometric measures, SMC coverage, and malaria infection data were collected from July to October. Malaria episodes were monitored through passive case detection between SMC cycles. Mixed-effects Poisson regression models estimated associations with malaria incidence and assessed changes in nutritional status and adherence to SMC campaign. Results: SMC coverage was high, with over 80% of children completing at least three rounds in both groups. Despite similar coverage, malnourished children had higher prevalence of Plasmodium falciparum infection (6.5% vs 2.6%; OR = 2.1, 95% CI 1.3-3.7) and higher clinical malaria incidence (9.1 vs 6.0 per 100 person-months; IRR = 1.4, 95% CI 1.0-2.0). Increased malaria risk was associated with baseline malnutrition (IRR = 1.6, 95% CI: 1.0-2.5) and receiving < 3 rounds (IRR = 3.0, 95% CI: 1.4-6.5). The interaction between nutritional status and SMC exposure was not significant (IRR = 0.8, 95% CI 0.2-3.6, p = 0.746). Improvements in nutritional indicators were observed among children completing 3-4 rounds in both groups. Conclusion: Malnutrition was independently associated with increased malaria risk, however adherence to routine SMC campaigns reduces the risk of malaria and improves nutritional status. Thus, integrating nutritional intervention with SMC is needed to enhance Child health in high-burden settings.

  • Open Access

    Seasonal Malaria Chemoprevention Therapy in Children Up To 9 Years of Age: Protocol for a Cluster-Randomized Trial Study

    by Mahamoudou Toure, Jeffrey G Shaffer, Daouda Sanogo, Soumba Keita, Moussa Keita, Fousseyni Kane, Bourama Traore, Djeneba Dabitao, Aissata Kone, Cheick Oumar Doumbia, et al.

    Background: Seasonal malaria chemoprevention (SMC) is recommended by the World Health Organization for the sub-Sahel region in sub-Saharan Africa for preventing malaria in children 3 months old to younger than 5 years. Since 2016, the Malian National Malaria Control Program has deployed SMC countrywide during its high malaria transmission season at a rate of 4 monthly cycles annually. The standard SMC regimen includes sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ). Resistance against SP is suspected to be rising across West Africa; therefore, assessing the effectiveness of an alternative antimalarial drug for SMC is needed to provide a second-line regimen when it is ultimately needed. It is not well understood whether SMC effectively prevents malaria in children aged 5 years or older. Objective: The primary goal of the study is to compare 2 SMC regimens (SP-AQ and dihydroartemisinin-piperaquine [DHA-PQ]) in preventing uncomplicated Plasmodium falciparum malaria in children 3 months to 9 years old. Secondly, we will assess the possible use of DHA-PQ as an alternative SMC drug in areas where resistance to SP or AQ may increase following intensive use. Methods: The study design is a 3-arm cluster-randomized design comparing the SP-AQ and DHA-PQ arms in 2 age groups (younger than 5 years and 5-9 years) and a control group for children aged 5-9 years. Standard SMC (SP-AQ) for children younger than 5 years was provided to the control arm, while SMC with SP-AQ was delivered to children aged 3 months to 9 years (arm 2), and SMC with DHA-PQ will be implemented in study arm 3 for children up to 9 years of age. The study was performed in Mali’s Koulikoro District, a rural area in southwest Mali with historically high malaria transmission rates. The study’s primary outcome is P falciparum incidence for 2 SMC regimens in children up to 9 years of age. Should DHA-PQ provide an acceptable alternative to SP-AQ, a plausible second-line prevention option would be available in the event of SP resistance or drug supply shortages. A significant byproduct of this effort included bolstering district health information systems for rapid identification of severe malaria cases. Results: The study began on July 1, 2019. Through November 2022, a total of 4556 children 3 months old to younger than 5 years were enrolled. Data collection ended in spring 2023, and the findings are expected to be published later in early 2024. Conclusions: Routine evaluation of antimalarial drugs is needed to establish appropriate SMC age targets. The study goals here may impact public health policy and provide alternative therapies in the event of drug shortages or resistance. Trial Registration: ClinicalTrials.gov NCT04149106, https://clinicaltrials.gov/ct2/show/NCT04149106 International Registered Report Identifier (IRRID): DERR1-10.2196/51660


  • Open Access

    Seasonal Malaria Chemoprevention Therapy in Children Up To 9 Years of Age: Protocol for a Cluster-Randomized Trial Study (Preprint)

    by Mahamoudou Toure, Jeffrey G Shaffer, Daouda Sanogo, Soumba Keita, Moussa Keita, Fousseyni Kane, Bourama Traore, Djeneba Dabitao, Aissata Kone, Cheick Oumar Doumbia, et al.

    BACKGROUND Seasonal malaria chemoprevention (SMC) is recommended by the World Health Organization for the sub-Sahel region in sub-Saharan Africa for preventing malaria in children 3 months old to younger than 5 years. Since 2016, the Malian National Malaria Control Program has deployed SMC countrywide during its high malaria transmission season at a rate of 4 monthly cycles annually. The standard SMC regimen includes sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ). Resistance against SP is suspected to be rising across West Africa; therefore, assessing the effectiveness of an alternative antimalarial drug for SMC is needed to provide a second-line regimen when it is ultimately needed. It is not well understood whether SMC effectively prevents malaria in children aged 5 years or older. OBJECTIVE The primary goal of the study is to compare 2 SMC regimens (SP-AQ and dihydroartemisinin-piperaquine [DHA-PQ]) in preventing uncomplicated Plasmodium falciparum malaria in children 3 months to 9 years old. Secondly, we will assess the possible use of DHA-PQ as an alternative SMC drug in areas where resistance to SP or AQ may increase following intensive use. METHODS The study design is a 3-arm cluster-randomized design comparing the SP-AQ and DHA-PQ arms in 2 age groups (younger than 5 years and 5-9 years) and a control group for children aged 5-9 years. Standard SMC (SP-AQ) for children younger than 5 years was provided to the control arm, while SMC with SP-AQ was delivered to children aged 3 months to 9 years (arm 2), and SMC with DHA-PQ will be implemented in study arm 3 for children up to 9 years of age. The study was performed in Mali’s Koulikoro District, a rural area in southwest Mali with historically high malaria transmission rates. The study’s primary outcome is P falciparum incidence for 2 SMC regimens in children up to 9 years of age. Should DHA-PQ provide an acceptable alternative to SP-AQ, a plausible second-line prevention option would be available in the event of SP resistance or drug supply shortages. A significant byproduct of this effort included bolstering district health information systems for rapid identification of severe malaria cases. RESULTS The study began on July 1, 2019. Through November 2022, a total of 4556 children 3 months old to younger than 5 years were enrolled. Data collection ended in spring 2023, and the findings are expected to be published later in early 2024. CONCLUSIONS Routine evaluation of antimalarial drugs is needed to establish appropriate SMC age targets. The study goals here may impact public health policy and provide alternative therapies in the event of drug shortages or resistance. CLINICALTRIAL ClinicalTrials.gov NCT04149106, https://clinicaltrials.gov/ct2/show/NCT04149106 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/51660